Abstract PS11-18: Ceralasertib (cer) in combination with olaparib (ola) in patients (pts) with advanced breast cancer (BC): Results of phase I expansion cohorts
Year: 2021
Type: conference-abstract
Source: Cancer Research
Authors: Emma Dean, Matthew G Krebs, Seock-Ah Im, Mario Campone, Sophie Postel-Vinay, Tobias Arkenau, Juanita Lopez, Wassim Abida, Duncan Jodrell, Keun-Wook Lee, SunYoung Rha, Irene Kang, Rebecca Roylance, Graeme Parr, Claire Smith, Andrew Goldwin, Elhan Sanay, Natasha Lukashchuk, Alan Lau, Andrew Pierce, Bienvenu Loembe
Institutions: AstraZeneca (United Kingdom), University of Manchester, The Christie NHS Foundation Trust, Seoul National University Hospital, Institut Gustave Roussy, Sarah Cannon Research Institute, Royal Marsden NHS Foundation Trust, Memorial Sloan Kettering Cancer Center, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Seoul National University, Seoul National University Bundang Hospital, Yonsei University, Yonsei University Health System, Yonsei Cancer Hospital, University of Southern California, University College London
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3132959103